Ningbo Joyson Electronic Corp. (00699) suggests appointing Wang Wenhai as an independent non-executive director.
China Electronics (00699) announced that Professor Wei Xuezhe (Professor Wei) will not be re-elected at the annual general meeting due to the board's succession arrangements and personal future work plans. After the appointment of a successor director is approved at the annual general meeting, he will resign from the position of independent non-executive director, chairman of the nomination, remuneration and assessment committee, and member of the board's strategy and ESG committee.
Ningbo Joyson Electronic Corp. (00699) has announced that Professor Wei Xuezhe (Professor Wei) will not be re-elected at the annual general meeting due to the board's succession arrangements and personal future work plans. Upon approval of the appointment of successor directors at the annual general meeting, Professor Wei will step down as an independent non-executive director, chairman of the nomination, remuneration and appraisal committee, and member of the board's strategic and ESG committee.
The board has recommended the re-election of directors, and in light of Professor Wei Xuezhe's retirement, has proposed the appointment of Mr. Wang Wenhai as an independent non-executive director (proposed appointment) to form the twelfth board of directors. The term will be three years from the date of approval of the relevant resolution at the annual general meeting.
Related Articles

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


